Comparative renal risk of long-term use of beta-lactams in combination with vancomycin across the continuum of care.

Dolly, Lauren M; Rivera, Christina G; Jensen, Kelsey L; Mara, Kristin C; Schreier, Diana J; Virk, Abinash; Arensman Hannan, Kellie N

Dolly, Lauren M; Rivera, Christina G; Jensen, Kelsey L; Mara, Kristin C; Schreier, Diana J; Virk, Abinash; Arensman Hannan, Kellie N.

Afiliação

Dolly LM; Department of Pharmacy, U.S. Department of Veterans Affairs, 2501 W 22nd Street, Sioux Falls, SD 57105, US.
Rivera CG; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Jensen KL; Department of Pharmacy, Mayo Clinic Health System, Austin, MN, USA.
Mara KC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Schreier DJ; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Virk A; Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
Arensman Hannan KN; Department of Pharmacy, Mayo Clinic Health System, 1025 Marsh Street, Mankato, MN 56001, USA.

Ther Adv Infect Dis ; 10: 20499361231189589, 2023.

Article em En | MEDLINE | ID: mdl-37576023

Palavras-chave

OPAT; beta-lactams; nephrotoxicity; vancomycin

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Infect Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google